Decitabine/Tetrahydrouridine A 5/250 mg clinical trials

A multicentre trial evaluating the efficacy and safety of oral decitabine-tetrahydrouridine (NDec) in patients with sickle cell disease

This study is testing a new combination medicine for sickle cell disease. It aims to see if it can improve a patient's red blood cells and overall health over about a year, while also checking for any side effects.